R&D channel feed

Sino­vac posts pos­i­tive PhI/II da­ta for their Covid-19 vac­cine as re­searchers rush in­to a piv­otal test

5 years ago
Coronavirus

UCB flash­es the da­ta be­hind its pos­i­tive pso­ri­a­sis read­outs. Can it com­pete in a crowd­ed field?

5 years ago

Can­cer drug­mak­er Agios of­fers promis­ing da­ta from two stud­ies test­ing blood dis­or­der drug

5 years ago
Deals

Mod­er­na bur­nish­es its PhI­II-ready Covid-19 vac­cine with promis­ing mouse da­ta — which sug­gest one dose might be enough af­ter all

5 years ago
Coronavirus

Lenti­Glo­bin con­tin­ues to de­liv­er in lat­est sick­le cell up­date as blue­bird out­lines path to ac­cel­er­at­ed ap­proval, de­spite pa­tient death

5 years ago
Cell/Gene Tx

Apel­lis coun­ters Alex­ion’s cri­tique, clears up FDA ques­tions as block­buster de­ci­sion looms

5 years ago
FDA+

As­traZeneca spin­off scores maid­en FDA ap­proval, where it will field Alex­ion com­pe­ti­tion and an im­mi­nent Roche ri­val

5 years ago
Pharma
FDA+

Ver­tex and CRISPR spot­light an­oth­er im­por­tant gene edit­ing ad­vance in a march to a hoped-for cure

5 years ago
Cell/Gene Tx

It's all about the heart: Di­a­betes ma­jor No­vo Nordisk bets $725M up­front to buy car­dio-fo­cused As­traZeneca spin­off

5 years ago
Deals

Fu­eled with a fresh cash in­jec­tion, Cul­li­nan ex­pands its pipeline with a bid to de­vel­op a new com­bi­na­tion drug for the check­point class

5 years ago

Mod­er­na floors it in­to PhI­II with their Covid-19 vac­cine, plan­ning quick start with a thumbs-up from FDA on tri­al de­sign, dosage

5 years ago
Coronavirus

Pfiz­er of­fers 3rd round of JAK da­ta, this time in kids. Can it com­pete?

6 years ago

De­nali scoots past a set­back with bare­ly a scratch, quick­ly call­ing up a back­up Alzheimer’s play­er on the bench

6 years ago

Covid-19 roundup: Fau­ci talks pric­ing, dis­parate im­pact and the virus’s en­dur­ing mys­ter­ies; Chi­na to of­fer ex­per­i­men­tal vac­cines to over­seas work­ers

6 years ago
Coronavirus

King Keytru­da floun­ders in an­oth­er piv­otal can­cer study. And that may spur doubts about Mer­ck­'s stay­ing pow­er

6 years ago

Re­gen­eron joins $100M round for DNAnexus and its cloud-com­put­ing DNA soft­ware

6 years ago
AI

Lean­ing on BD to re­vive weak pipeline, Lund­beck plans to cut up to 160 jobs in R&D re­struc­tur­ing

6 years ago
People

Sarep­ta re­veals pos­i­tive re­sults in limb-gir­dle gene ther­a­py tri­al. What does that mean for DMD?

6 years ago
Cell/Gene Tx

NIH — and some fa­mil­iar play­ers — back a PhII Alzheimer’s gam­ble in an­oth­er stab at the amy­loid hy­poth­e­sis

6 years ago

Al­ny­lam sets up 3rd po­ten­tial RNAi ap­proval with a show­case of pos­i­tive lumasir­an da­ta

6 years ago

Leg­end fetch­es $424 mil­lion, emerges as biggest win­ner yet in pan­dem­ic IPO boom as shares soar

6 years ago
Financing

As it hap­pened: A bid­ding war for an an­tibi­ot­ic mak­er in a mar­ket that has rav­aged its peers

6 years ago

Gilead bol­sters its case for block­buster hope­ful fil­go­tinib as FDA pon­ders its de­ci­sion

6 years ago

Can a small biotech suc­cess­ful­ly tack­le an Ever­est climb like Alzheimer’s? Athi­ra has $85M and some in­flu­en­tial back­ers ready to give it a shot

6 years ago
Financing
First page Previous page 198199200201202203204 Next page Last page
A service from the Financial Times